Zafgen Inc (ZFGN) Stock Price & Overview
NASDAQ:ZFGN
Current stock price
The current stock price of ZFGN is 0.99 null. Today ZFGN is down by -14.66%. In the past month the price increased by 26.16%. In the past year, price decreased by -45.9%.
ZFGN Key Statistics
- Market Cap
- 37.095M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.81
- Dividend Yield
- N/A
ZFGN Stock Performance
ZFGN Stock Chart
ZFGN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ZFGN. When comparing the yearly performance of all stocks, ZFGN is a bad performer in the overall market: 88.88% of all stocks are doing better.
ZFGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZFGN. ZFGN has a bad profitability rating. Also its financial health evaluation is rather negative.
ZFGN Earnings
ZFGN Forecast & Estimates
ZFGN Financial Highlights
Over the last trailing twelve months ZFGN reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 52.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.7% | ||
| ROE | N/A | ||
| Debt/Equity | 0.26 |
ZFGN Ownership
About ZFGN
Company Profile
Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.
Company Info
Zafgen Inc
3 Center Plaza Suite 610
BOSTON MA 02108
CEO: Jeffrey Hatfield
Phone: 617-622-4003
Zafgen Inc / ZFGN FAQ
What does ZFGN do?
Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.
What is the current price of ZFGN stock?
The current stock price of ZFGN is 0.99 null. The price decreased by -14.66% in the last trading session.
Does ZFGN stock pay dividends?
ZFGN does not pay a dividend.
What is the ChartMill rating of Zafgen Inc stock?
ZFGN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.